<DOC>
	<DOCNO>NCT00193115</DOCNO>
	<brief_summary>This protocol evaluate feasibility toxicity dose-dense docetaxel follow doxorubicin cyclophosphamide support give adjuvant neoadjuvant treatment woman node positive high risk breast cancer</brief_summary>
	<brief_title>Docetaxel Followed Doxorubicin Plus Cyclophosphamide Node Positive High-Risk Primary Breast Cancer</brief_title>
	<detailed_description>Upon determination eligibility , patient receive : Neoadjuvant Docetaxel + Doxorubicin + Cyclophosphamide + Surgery Adjuvant patient enter study surgery receive Docetaxel+ Doxorubicin + Cyclophosphamide . Patients treat lumpectomy undergo postoperative radiation therapy completion chemotherapy . Patients positive estrogen and/or progesterone receptor begin anti-estrogen therapy last course chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>To include study , must meet following criterion : Histologically proven breast cancer Females , age great 18 year Ability perform activites daily live minimal assistance Normal cardiac function Adequate bone marrow , liver kidney Signed informed consent prior begin specific protocol procedure You participate study follow apply : Prior systemic anticancer therapy breast cancer Prior anthracycline taxane base chemotherapy malignancy Pregnant breastfeeding woman . Preexisting moderate severe motor sensory neurotoxicity Other serious illness medical condition Please note : There additional inclusion/exclusion criterion . The study center determine meet criterion . If qualify trial , study personnel explain reason . If qualify , study personnel explain trial detail answer question may .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>